menu search

BCLI / FDA panel rejects ALS treatment from Brainstorm Cell Therapeutics

FDA panel rejects ALS treatment from Brainstorm Cell Therapeutics
A U.S. Food and Drug Administration advisory committee voted against a treatment from BrainStorm Cell Therapeutics BCLI, -8.35% for amyotrophic lateral sclerosis, or ALS. Read More
Posted: Sep 27 2023, 19:36
Author Name: Market Watch
Views: 111088

BCLI News  

BrainStorm shares plunge 56% after FDA advisers reject ALS cell therapy

By Proactive Investors
September 28, 2023

BrainStorm shares plunge 56% after FDA advisers reject ALS cell therapy

Shares of BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) plummeted by 56% in early trading after the company's treatment for amyotrophic lateral scle more_horizontal

Brainstorm Cell Therapeutics shares fall more than 50% after FDA advisors vote down ALS treatment

By Market Watch
September 28, 2023

Brainstorm Cell Therapeutics shares fall more than 50% after FDA advisors vote down ALS treatment

BrainStorm Cell Therapeutics Inc. BCLI, -8.35% shares fell 56% premarket on Thursday after advisors to the U.S. Food and Drug Administration on Wednes more_horizontal

FDA panel rejects ALS treatment from Brainstorm Cell Therapeutics

By Market Watch
September 27, 2023

FDA panel rejects ALS treatment from Brainstorm Cell Therapeutics

A U.S. Food and Drug Administration advisory committee voted against a treatment from BrainStorm Cell Therapeutics BCLI, -8.35% for amyotrophic latera more_horizontal

US FDA panel votes against BrainStorm's ALS therapy

By Reuters
September 27, 2023

US FDA panel votes against BrainStorm's ALS therapy

The U.S. health regulator's advisers on Wednesday voted against BrainStorm Cell Therapeutics' therapy for patients with amyotrophic lateral sclerosis more_horizontal

BrainStorm Cell shares fall as FDA reviewers raise doubts over effectiveness of ASL therapy

By Proactive Investors
September 25, 2023

BrainStorm Cell shares fall as FDA reviewers raise doubts over effectiveness of ASL therapy

Shares of BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) fell almost 40% on Monday morning after Food and Drug Administration (FDA) staff reviewers e more_horizontal

FDA staff reviewers raise concerns over BrainStorm Cell's ALS therapy

By Reuters
September 25, 2023

FDA staff reviewers raise concerns over BrainStorm Cell's ALS therapy

The U.S. Food and Drug Administration's staff reviewers raised concerns on Monday over the safety and efficacy of BrainStorm Cell Therapeutics' amyotr more_horizontal

Brainstorm Cell Therapeutics: I Anticipate A Positive AdCom But There Are Major Risks

By Seeking Alpha
September 15, 2023

Brainstorm Cell Therapeutics: I Anticipate A Positive AdCom But There Are Major Risks

BCLI has completed a phase 3 trial in ALS. Despite not meeting the primary endpoint BCLI is still applying for approval and an AdCom meeting is schedu more_horizontal

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Quarter - Brainstorm Cell (NASDAQ:BCLI), Cosmos Health (NASDAQ:COSM)

By Benzinga
July 27, 2023

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Quarter - Brainstorm Cell (NASDAQ:BCLI), Cosmos Health (NASDAQ:COSM)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. more_horizontal


Search within

Pages Search Results: